ACP 105 Capsule

ACP-105 can specifically bind to the androgen receptor (AR) in the body. Androgen receptors are widely distributed in the human body, including tissues such as muscles, bones, the prostate, and the central nervous system. When ACP-105 binds to the androgen receptor, it changes the conformation of the receptor, making it easier to bind to DNA and thereby affecting the transcription and expression of genes.

Unlike traditional steroid hormones, ACP-105 has the characteristic of selective action. It mainly has a high affinity for androgen receptors in muscle and bone tissues, while has a relatively low affinity for androgen receptors in tissues such as the prostate. This selective effect enables ACP-105 to promote muscle growth and increase bone density while reducing side effects on tissues such as the prostate, such as lowering the risks of benign prostatic hyperplasia and prostate cancer.

After ACP-105 binds to androgen receptors, it activates a series of signaling pathways related to muscle growth and bone metabolism. For example, it can activate the PI3K-Akt signaling pathway, which plays an important role in the growth, proliferation and survival of cells. In muscle cells, the activation of the PI3K-Akt signaling pathway can promote protein synthesis and inhibit protein breakdown, thereby increasing muscle mass. Meanwhile, ACP-105 can also activate the Wnt/β-catenin signaling pathway, which is crucial for bone formation and maintenance. By activating the Wnt/β-catenin signaling pathway, ACP-105 can promote the proliferation and differentiation of osteoblasts, increase bone mineral density, and prevent osteoporosis.

Promoting protein synthesis: ACP-105 can increase the activity of mTOR in muscle cells by activating androgen receptors and related signaling pathways. mTOR is a serine/threonine protein kinase and plays a key role in protein synthesis. The increase in mTOR activity can promote the biosynthesis of ribosomes and the initiation of protein translation, thereby accelerating the synthesis of muscle proteins.

Inhibiting muscle breakdown: In addition to promoting protein synthesis, ACP-105 can also inhibit muscle breakdown. It can reduce the activity of the ubiquitin-proteasome system in muscle cells, which is the main pathway for muscle protein breakdown. By inhibiting the ubiquitin-proteasome system, ACP-105 can reduce the breakdown rate of muscle proteins and maintain muscle mass.

Increase bone mineral density: ACP-105 has a selective effect on androgen receptors in bone tissue, which can promote the proliferation and differentiation of osteoblasts and inhibit the activity of osteoclasts. Osteoblasts are responsible for the formation of bones, while osteoclasts are responsible for the absorption of bones. By regulating the balance of osteoblasts and osteoclasts, ACP-105 can increase bone mineral density, improve the microstructure of bones, and enhance the strength and toughness of bones.

Preventing osteoporosis: Osteoporosis is a common bone disease, mainly characterized by decreased bone density and increased bone fragility. ACP-105 can prevent the occurrence and development of osteoporosis and reduce the risk of fractures by increasing bone density and improving bone quality.

Although ACP-105 has a selective effect, it may still cause some side effects. For example, long-term use of ACP-105 may inhibit the secretion of endogenous testosterone, resulting in an imbalance of hormone levels. This is because exogenous ACP-105 can feedback inhibit the hypothalamic-pituitary-gonadal axis, reduce the secretion of gonadotropin-releasing hormone (GnRH), follicle-stimulating hormone (FSH), and luteinizing hormone (LH), and thereby affect the function of the testicles. In addition, ACP-105 may also have certain effects on the liver, cardiovascular system, etc. However, the specific mechanism is not yet fully clear and further research is needed to clarify it.

Muscle-related diseases: ACP-105 may have potential in the treatment of atrophic muscular diseases (such as muscular dystrophy and cancer cachexia). As a selective androgen receptor modulator (SARM), it can target androgen receptors in muscle tissue, promoting muscle growth and reducing abnormal protein breakdown in muscle cells. This dual effect is expected to effectively improve the muscle strength and functional status of patients with atrophic muscular diseases, thereby enhancing their quality of life and reducing dependence on care. However, there are no large-scale clinical trials to confirm its safety and efficacy at present, and further research is needed to clarify its optimal dosage and long-term effects.

Osteoporosis treatment: The enhancing effect of ACP-105 on bone mineral density makes it have potential application value in the treatment of osteoporosis, especially in postmenopausal women and elderly populations with age-related bone loss. Compared with traditional anti-osteoporosis drugs (such as bisphosphonates), SARMs like ACP-105 may function through different mechanisms-they can regulate bone metabolism by activating androgen receptors in bone tissue, promoting osteoblast proliferation and inhibiting osteoclast activity. This unique mechanism provides more options for clinical treatment of osteoporosis. However, large-scale clinical trials are also needed to verify its long-term efficacy and safety, as well as its potential impact on bone metabolism balance.

Rehabilitation medicine: In postoperative rehabilitation or recovery from sports injuries, ACP-105 may shorten the rehabilitation time by accelerating muscle repair and bone healing. However, this application requires a strict assessment of its risk of side effects, especially when used in a non-disease state.

Clinical trials and Validation

Regulatory compliance

Technological innovation